Branching out from diabetes? Novo Nordisk shells out the big bucks for Prothena's ATTR amyloidosis pipeline
Ostensibly looking to branch out from its diabetes franchises, Novo Nordisk is making a major play into the amyloid space — and paying a pretty penny to do so.
The Danish pharma company is grabbing a Prothena antibody and wider program in ATTR amyloidosis for $100 million upfront, the companies announced Monday morning. Prothena’s candidate in question is the PRX004 compound, a monoclonal antibody designed to deplete amyloid deposits in hereditary and wild type ATTR amyloidosis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.